Non-Melanoma Skin Cancer Aggravation in Polycythemia Vera: Triggered by Ruxolitinib and Silenced With an IFN/Cemiplimab

Non-Melanoma Skin Cancer Aggravation in Polycythemia Vera: Triggered by Ruxolitinib and Silenced With an IFN/Cemiplimab

Authors

  • Efterpi Zafiriou Department of Dermatology, Faculty of Medicine, School of Health Sciences, University General Hospital of Larissa, University of Thessaly, Larissa, Greece
  • Emmanouil Karampinis Department of Dermatology, Faculty of Medicine, School of Health Sciences, University General Hospital of Larissa, University of Thessaly, Larissa, Greece
  • Vasileios Papadopoulos Department of Oncology, University General Hospital of Larissa, Larissa, Greece
  • Georgia Stefani Department of Hematology, UHL, University of Thessaly Medical School, Larissa, Greece
  • Athanasios Kotsakis Department of Oncology, University General Hospital of Larissa, Larissa, Greece
  • George Vassilopoulos Department of Hematology, UHL, University of Thessaly Medical School, Larissa, Greece

Keywords:

cutaneous squamous cell carcinoma, Ruxolitinib, anti-PD-1, interferon alpha2b

References

Lin JQ, Li SQ, Li S, et al. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis. J Am Acad Dermatol. 2022;86(2):339-344. DOI:10.1016/j.jaad.2021.10.004.Lin JQ, Li SQ, Li S, et al. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis. J Am Acad Dermatol. 202;86(2):339-344. DOI: 10.1016/j.jaad.2021.10.004.. PMID: 34648874.

Razaghi A, Razaghi A, Durand-Dubief M, Brusselaers N, Björnstedt M. Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy. Front Immunol. 2023;14:1249330. DOI: 10.3389/fimmu.2023.1249330. PMID: 37691915. PMCID: PMC10484344.Durand-Dubief M, Brusselaers N, Björnstedt M. Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy. Front Immunol. 2023;14:1249330. Published 2023 Aug 24. DOI:10.3389/fimmu.2023.1249330

Downloads

Published

2025-01-29

How to Cite

1.
Zafiriou E, Karampinis E, Papadopoulos V, Stefani G, Kotsakis A, Vassilopoulos G. Non-Melanoma Skin Cancer Aggravation in Polycythemia Vera: Triggered by Ruxolitinib and Silenced With an IFN/Cemiplimab. Dermatol Pract Concept. 2025;15(1):4642. doi:10.5826/dpc.1501a4642

Share